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Abstract
Background: The global pandemic of coronavirus disease 2019 (COVID-19) is caused by infection with the SARSCoV-2 virus. Currently, there are three approved vaccines against SARS-CoV-2 in the USA, including two based on
messenger RNA (mRNA) technology that has demonstrated high vaccine efficacy. We sought to characterize
humoral immune responses, at high resolution, during immunization with the BNT162b2 (Pfizer-BioNTech) vaccine
in individuals with or without prior history of natural SARS-CoV-2 infection.
Methods: We determined antibody responses after each dose of the BNT162b2 SARS-CoV-2 vaccine in individuals
who had no prior history of SARS-CoV-2 infection (seronegative) and individuals that had previous viral infection 30–60
days prior to first vaccination (seropositive). To do this, we used both an antibody isotype-specific multiplexed beadbased binding assays targeting multiple SARS-CoV-2 viral protein antigens and an assay that identified potential SARSCoV-2 neutralizing antibody levels. Moreover, we mapped antibody epitope specificity after immunization using SARSCoV-2 spike protein peptide arrays.
Results: Antibody levels were significantly higher after a single dose in seropositive individuals compared to
seronegative individuals and were comparable to levels observed in seronegative individuals after two doses. While
IgG was boosted by vaccination for both seronegative and seropositive individuals, only seronegative individuals had
increased IgA or IgM antibody titers after primary immunization. We identified immunodominant peptides targeted on
both SARS-CoV-2 spike S1 and S2 subunits after vaccination.
Conclusion: These findings demonstrated the antibody responses to SARS-CoV-2 immunization in seropositive and
seronegative individuals and provide support for the concept of using prior infection history as a guide for the
consideration of future vaccination regimens. Moreover, we identified key epitopes on the SARS-CoV-2 spike protein
that are targeted by antibodies after vaccination that could guide future vaccine and immune correlate development.
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Background
Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) is a novel betacoronavirus causing coronavirus
disease 2019 (COVID-19) [1, 2]. Humoral immune responses play critical roles in protecting individuals against
SARS-CoV-2 infection, particularly through the elicitation
of neutralizing antibodies. There is an urgent need to
understand humoral immune responses to SARS-CoV-2
and how these responses contribute to disease severity
and vaccine-induced immunity. Early antibody responses
targeting the SARS-CoV-2 spike protein (S) or nucleocapsid protein (NP) are detectable soon after natural infection, within 20 days of symptom onset, and have been
demonstrated to be immunoglobulin M (IgM), IgG, and
IgA isotypes with varying kinetics of development [3–7].
While IgG and IgM antibody responses have been more
extensively studied in SARS-CoV-2 infection, there have
been reports that IgA antibodies contribute to the early
neutralizing antibody response [8]. Antibodies that can
neutralize SARS-CoV-2 and prevent infection are targeted
for therapeutics and vaccine development [9, 10].
There are two currently US Food and Drug Administration (FDA)-approved SARS-CoV-2 vaccines that are
based on messenger RNA (mRNA) platform technology
in the United States (US) and have demonstrated greater
than 90% efficacy after two doses in phase III clinical trials (BNT162b2/Pfizer; mRNA-1273/Moderna) [11, 12]).
The phase III trials of the mRNA vaccines primarily
studied the immune responses in individuals who had
no prior history of SARS-CoV-2 infection. Although
immune correlates of protection for SARS-CoV-2
vaccines have not yet been defined in humans, animal
studies with similar vaccine formulations have identified
levels of neutralizing antibodies as one potential correlate of protective efficacy in rhesus macaques [13, 14].
With over 31 million cases of COVID-19 that have
been documented in the US and high observed seroprevalence [15], it is critical to define the immune
responses after vaccination in individuals with previous
infection. We and others have demonstrated that after a
single dose of SARS-CoV-2 mRNA vaccine, individuals
with previous infection have more robust antibody
responses when compared to infection-naïve individuals
[16–19]. This boost of preexisting antibody immunity
from prior infection may be considered when deciding
whether a single or double dose is required for vaccinemediated protection in individuals with prior history of
infection.
Here, we report antibody responses in seronegative
and seropositive healthcare workers at baseline and after
each of the two doses of the BNT162b2 SARS-CoV-2
vaccine. We determined the levels of antibodies of multiple immunoglobulin subclasses to different viral antigens, identified potential SARS-CoV-2 neutralizing
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antibody levels, and identified key immunodominant
peptides that are targeted on the SARS-CoV-2 spike protein after immunization.

Methods
Individuals and sample collection

We enrolled healthcare workers from our children’s hospital prior to the administration of the Pfizer BNT162b2
COVID-19 vaccine. Peripheral blood was collected before vaccination at baseline (week 0), after primary
immunization (week 3), and secondary booster
immunization (week 7) from healthcare workers who
had no known history of infection (N = 152) or previous
laboratory-confirmed SARS-CoV-2 infection 30–60 days
(N = 42) prior to the administration of the BNT162b2
vaccine (administered at week 0 and week 3). This population consisted of mostly adult middle aged, white, females who did not identify as Hispanic or Latino
(Supplementary Table 1). The SARS-CoV-2 vaccine
specimens were collected at Children’s Mercy Kansas
City and were reviewed and approved by the Children’s
Mercy IRB. Serum or plasma was utilized to perform the
immunoassays that were isolated from venous whole
blood collection and stored in frozen in ultra-low
temperature freezers until use.
SARS-CoV-2 viral antigen multiplexed binding assay

To measure antibody levels to SARS-CoV-2 spike subunit
proteins (spike subunit 1 (S1), spike subunit 2 (S2),
receptor-binding domain (RBD)) and nucleocapsid protein
(NP) antigens, we utilized a bead-based multiplex assay
based on the Luminex xMAP technology using reagent
kits that had secondary antibodies that were specific for
immunoglobulin isotypes (IgG, IgM, IgA). We used the
following kits: IgG (Millipore, #HC19SERG1-85 K), IgM
(Millipore, #HC19SERM1-85 K), and IgA (Millipore,
#HC19SERA1-85 K) following standard manufacture protocols. Each kit provided the same sets of SARS-CoV-2
antigen conjugated beads (S1, S2, RBD, NP) along with 4
positive control beads and a negative control bead set.
The positive control beads were beads coated with different concentrations of IgG, IgM, or IgA (depending on the
isotype kit utilized). The negative control beads did not
have antigen conjugated to determine nonspecific binding.
The 4 antigen-conjugated beads, 4 positive control beads,
and 1 negative control beads were mixed and incubated
with each plasma sample that was diluted 1:100 with assay
buffer. With each assay plate, at least two sample wells
with only buffer and no plasma were included to determine assay background. Finally, PE-anti-human IgG, IgM,
or IgA conjugate detection antibodies were utilized to determine antibody isotype responses to each of the SARSCoV-2 antigens. Using the positive control beads, we determined the inter-assay (plate-to-plate) coefficient of
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variation (CV) for each assay. We determined that the
CVs were 5.16%, 7.42%, and 11.45% for the IgG, IgM, and
IgA assays, respectively. In order to acquire and analyze
data, we utilized the Luminex analyzer (MAGPIX) and
Luminex xPONENT acquisition software. Samples were
run in technical duplicate and after acquisition Net MFI
was utilized which is MFI with background well (no
plasma) MFI subtracted. Positive control beads were utilized to ensure positive detection of the well and to identify any inter- and/or intra-assay technical variation. We
next determined the level of nonspecific binding by using
the negative control samples MFI (beads without antigen
mixed with plasma) for each isotype (IgG, IgM, IgA). The
IgG had the highest background MFI, so we used the average MFI plus the standard deviation of the IgG samples to
set the detection threshold for IgG, IgM, and IgA isotype
assays (442 MFI).
SARS-CoV-2 viral neutralizing antibody assays

To detect viral neutralizing antibodies the SARS-CoV-2
Surrogate Virus Neutralization Test kit was utilized
(Genscript, #L00847) according to the standard protocol.
Samples were run in duplicate with blocking values averaged. This kit detects antibodies that can block the interaction between the receptor-binding domain of the viral
spike glycoprotein with the angiotensin-converting enzyme 2 (ACE2) cell surface receptor and has been approved by the FDA for emergency use. Plasma samples
along with positive (anti-RBD antibody) and negative
(buffer only) were incubated with a Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD
fragment. The mixture was then added to a capture plate
that was coated with the human ACE2 protein. The unbound HRP-RBD will bind to the plate. After washing, 3,
3′,5,5′-tetramethylbenzidine (TMB) solution was added
to develop the HRP signal and was read at 450 nm in a
microtiter plate reader. The absorbance of the sample is
inversely dependent on the titer of the anti-SARS-CoV-2
neutralizing antibodies. Inhibition was calculated by (1 −
OD value of sample/OD value of negative control) × 100
which gives percent inhibition. A cutoff of ≥ 30% is considered positive for SARS-CoV-2 neutralizing antibody.
Plasma samples were diluted 1:10 for all samples and 1:
100 for a more dilute assay of seropositive samples at
week3 and week 7 timepoints.
SARS-CoV-2 protein and peptide microarray

Plasma samples were diluted 1:200 and used to probe
a single SARS-CoV-2 protein and peptide microarray
(CDI Labs). After probing arrays with serum antibodies, the arrays were washed, labeled with an
Alexa647-anti-human IgG Fc secondary antibody and
scanned using a GenePix 4000B scanner. Array data
was collected using the MAGPIX software (Innopsys).
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Each protein or peptide was represented in triplicate
on the microarray. There were positive control proteins (human IgG, anti-human IgG, and ACE2_Fc)
and blank wells served as negative controls. The signal intensity was measured in the detection channel
635 nm (F635). The average of the F635 for each peptide was calculated and log2 transformed for graphing. Z-scores were calculated across all peptides for
each individual prior to t test analysis with Bonferroni
adjustment for multiple comparisons.

SARS-CoV-2 antigen IgG subclass (IgG1, IgG2, IgG3, IgG4)
binding

Antigens: SARS-CoV-2 spike protein RBD (Genscript #
Z03483), SARS-CoV2 nucleocapsid protein (Genscript
#Z03488), SARS-CoV-2 S1 subunit spike protein (Genscript #Z03501), SARS-CoV-2 S2 subunit spike protein
(R&D Systems #10594-CV) were all diluted to 1 μg/mL
in 0.1 M sodium bicarbonate and incubated on highbinding plates (corning #3369) overnight at 4 degrees.
Serum was diluted to 1:30 in superblock buffer with sodium azide followed by subsequent 1:3 dilutions until a
final dilution of 1:21870 was reached. Secondary antibodies were purchased from Southern Biotech: Mouse
Anti-Human IgG1 Fc-HRP (#9054-05), Mouse AntiHuman IgG2 Fc-HRP (#9060-05), Mouse Anti-Human
IgG3 Hinge-HRP (#9210-05), Mouse Anti-Human IgG4
Fc-HRP (#9200-05). Secondary antibody dilutions were
done in superblock buffer without sodium azide within
range of manufacturers recommendations: IgG1 1:6000,
IgG2 1:5000, IgG3 1:7000, IgG4 1:6000. SureBlue Reserve Microwell Substrate (VWR #95059-294) was added
to each well and incubated in the dark for 15 min. Absorbance was measured at 450 nm immediately after
0.33 N HCl Acid Stop solution was added to the plate.

Statistical analysis

All statistical analyses were performed using Prism 8.0
(GraphPad Software Inc.) software and R. For group comparisons, an unpaired nonparametric Wilcoxon-MannWhitney test was used with a two-tailed P value reported.
We used a P value significance threshold of P < 0.05. Both
the Wilcoxon-Mann-Whitney and descriptive statistical
analysis such as mean, median, and range were calculated
using non-transformed data. For the peptide microarray
data, the log2 fluorescence intensity was used for the heatmap and these values were transformed into Z-score
based on row (sample) for the Z-score plotting of the
group average. We selected Z-score values > 1 (one standard deviation above mean) to identify immunodominant
peptides within the vaccine group.
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Results
SARS-CoV-2 antibody responses after vaccination in
seropositive and seronegative individuals

Peripheral blood was collected before vaccination at baseline (week 0), after primary immunization (week 3), and
secondary booster immunization (week 7) from individuals who had no known history of infection (seronegative;
N = 152) or laboratory-confirmed SARS-CoV-2 infection
30–60 days (seropositive; N = 42) prior to the administration of the BNT162b2 vaccine (administered at week 0
and week 3). This population consisted of mostly adult
middle aged, white, females who did not identify as Hispanic or Latino (Additional file 1: Table S1).
We first measured immunoglobulin G (IgG) antibody
levels at the three timepoints (week 0, week 3, and week
7) to SARS-CoV-2 spike subunit proteins (spike subunit
1 (S1), spike subunit 2 (S2), receptor-binding domain
(RBD)) and nucleocapsid protein (NP) using a multiplexed bead-based binding assay. As expected at baseline, the seronegative group had low median
fluorescence intensity (MFI) for all four antigens (S1,
16.8; S2, 886.7; RBD, 218.2; NP, 482.9) whereas the seropositive group had significantly higher median antibody
binding levels (S1, 10793.3; S2, 12923; RBD, 16409.7;
NP, 20766). Cross-reactivity of pre-existing antibody immunity has been reported in the absence of SARS-CoV2 infection [20–24]. In parallel, we analyzed a group of
individuals that had peripheral blood collected prior to
the emergence of SARS-CoV-2 and the COVID-19 pandemic in the year 2019 (Additional file 1: Figure S1A).
We found that the median MFI of the groups (S1, 20.5;
S2, 732; RBD, 331.3; NP, 759.8) in the pre-pandemic individuals were similar to the baseline levels of the seronegative group prior to vaccination. Interestingly, the
MFI for RBD was consistently higher than S1 in the prepandemic samples and further study into the protein
background levels or conformation-dependent nature of
the antibody response should be performed. Thus, MFI
levels significantly above the seronegative individuals at
baseline or the individuals collected prior to the pandemic would represent elevation in antibody levels due
to vaccination or more recent SARS-CoV-2 infection.
The lowest median MFI in the seronegative group was
to the S1 protein, with a median MFI less than 20.5 for
the seronegative vaccine group or group sampled prior
to the COVID-19 pandemic (Additional file 1: Figure
S1). We identified six individuals at baseline who had S1
antibody levels MFI ≥ 1000, similar to the levels observed at baseline in the seropositive group. These individuals also had higher levels of antibody binding to the
other SARS-CoV-2 antigens tested and may have had
undiagnosed or asymptomatic infection prior to vaccination (Additional file 1: Figure S1B). After primary
immunization (week 3), both seronegative and

Page 4 of 12

seropositive individuals had significantly increased IgG
antibody titers to all three spike subunit antigens when
compared to baseline (S1, S2, RBD; P < 0.0001; Fig. 1A).
Furthermore, seropositive individuals had significantly
higher titers to all spike antigens when compared to
the seronegative group at week 3 after primary
immunization (P < 0.0001; Fig. 1A). The undiagnosed
individuals resembled seropositive participants in
week 3 serological assays and therefore we added
them to the seropositive group for subsequent analysis at week 7 (green points). While the NP is contained in the whole virus, only the SARS-CoV-2 spike
protein is a vaccine antigen. As expected, we found
higher NP antibody titers only in the group with
prior natural infection (seropositive), and there were
no significant changes in NP antibody levels after vaccination in either group (seropositive or seronegative)
(Fig. 1A). Four weeks after the second vaccine dose
(week 7), seronegative individuals had significantly increased antibody titers to all 3 spike subunit proteins
when compared to week 3 (P < 0.0001), whereas seropositive individuals had significant increases to S1
and S2 but not the RBD, with smaller magnitudes of
increases compared to week 3 levels. Antibody titers
in seropositive individuals at week 3 were comparable
to week 7 titers in seronegative individuals for S1 and
RBD; however, seropositive individuals had significantly higher S2 antibody levels at both week 3 and
week 7 when compared to seronegative individuals (P
< 0.0001; Fig. 1A).
We next used an assay that allows indirect detection
of SARS-CoV-2 neutralizing antibodies through determination of antibody blocking of SARS-CoV-2 RBD
binding to the human host viral receptor angiotensinconverting enzyme 2 (ACE2). This assay has been demonstrated to have a significant correlation with levels of
neutralizing antibodies determined by primary virus or
pseudovirus neutralization assays [25]. Levels of blocking
antibodies were significantly increased after primary vaccination (week 3) for both seropositive and seronegative
groups, and the seropositive group had significantly
higher blocking antibodies when compared to the seronegative group (P < 0.0001; Fig. 1B). The second vaccine
dose only significantly increased blocking for the seronegative group at week 7 (P < 0.0001; Fig. 1B). There
was no significant difference in blocking antibodies in
the seropositive group after the first vaccine dose (week
3) when compared to the seronegative group after the
second vaccine dose (week 7). The median percent
blocking for the seropositive samples was 96.3% at week
3 and 97.9% at week 7. We further performed an additional 10-fold dilution of the plasma samples in order to
determine if there were any increases in the magnitude
of neutralizing antibodies in seropositive individuals
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Fig. 1 Antibody response to SARS-CoV-2 mRNA vaccine. A Multiplex bead-based antibody binding assay that measures the IgG antibody response to
4 SARS-CoV-2 viral antigens (S1, S2, RBD, and NP). Median Fluorescent Intensity (MFI) is shown and background well subtraction has been used to
remove nonspecific signal. Each dot represents an individual at baseline before vaccine (week 0), 3 weeks after the first dose of vaccine (week 3) or 4
weeks after the second dose (week 7). Bars represent the group median. The number of individuals in each group are shown below the graphs.
Individuals with a previous history of SARS-CoV-2 infection (seropositive; blue), no previous history of infection (seronegative; red), and individuals with
possible undiagnosed infection (green). The dashed line indicates a threshold determined by the sum of the mean and standard deviation for the
negative control (beads without antigen). B Neutralization antibody proxy assay that determines the level of antibodies that block the RBD-ACE2
receptor-binding expressed as the percentage of binding that was blocked relative to control with no plasma (representing maximum binding). The
assay threshold for positivity was 30%. Each point represents an individual at baseline before the vaccine, 3 weeks after the first dose of vaccine (week
3) or 4 weeks after the second dose (week 7). Bars represent the group median. The number of individuals in each group are shown below the graphs.
Individuals with a previous history of SARS-CoV-2 infection (seropositive; blue), no previous history of infection (seronegative; red), and individuals with
possible undiagnosed infection (green). Statistical tests for significant differences between groups were unpaired, two-tailed Wilcoxon-Mann-Whitney
test with a significant threshold of P < 0.05
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after the second vaccine dose. Using this plasma dilution, we found that there was an increase in the seropositive group from week 3 (median 89.4%) to week 7
(median 93.4%) that was modest in magnitude but statistically significant (P = 0.02; Additional file 1: Figure S2).
The threshold for positive detection of SARS-CoV-2
neutralizing antibodies has been determined to be ≥ 30%
for this assay. Using this threshold as a marker of seropositivity after vaccination, there were 86.1% and 97.5%
of individuals who had antibody levels above the threshold after the first immunization in the seronegative and
seropositive/undiagnosed groups, respectively (Fig. 1B).
After the second dose, nearly all participants in both
groups had positive neutralizing antibody titers (seronegative: 99.2%; seropositive: 100%; Fig. 1B). These results demonstrated that individuals with prior SARSCoV-2 infection have higher magnitudes of binding and
neutralizing antibodies after a single dose that is equivalent to levels observed in seronegative individuals after
two vaccine doses. Moreover, seropositive individuals
only receive a minor increase in antibody binding magnitude after the second dose.

Impacts of sex and age on primary vaccine SARS-CoV-2
vaccine response

Next, we determined the contribution of sex and age to vaccine neutralizing antibody responses by stratifying the week
3 blocking assay results by sex and age. After the first vaccine
dose (week 3), no significant differences in blocking antibody
levels based on sex were detected (Fig. 2). However, we did
observe that older individuals (≥ 50 years of age) in the seronegative group had significantly lower blocking antibodies
compared to younger individuals (< 50 years of age) after
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primary immunization, but no significant difference in age
was observed for the seropositive group (P = 0.0003; Fig. 2).
SARS-CoV-2 IgM and IgA isotype response during
vaccination

While IgG isotype antibodies are the major surrogates of
vaccine and infection-mediated immunity, the kinetics
and contributions of IgM and IgA isotypes are less clear.
We found that IgM antibody responses to S1, S2, and
RBD were only significantly boosted after immunization
in the seronegative individuals, whereas the antibody
levels in seropositive individuals were not boosted and
even waned by week 7 (Fig. 3A). However, IgM levels at
baseline in the seropositive individuals remained significantly higher than levels elicited by two doses of vaccine
(week 7) in seronegative individuals (Fig. 3A). Similarly,
IgA antibody levels were only increased by vaccination
in seronegative individuals, with no significant change
during vaccination in seropositive individuals (Fig. 3B).
Only IgM S1 antibody levels had a significant increase in
seronegative individuals after the second dose, indicating
a limited contribution of secondary immunization to
IgM and IgA antibody responses (Fig. 3A, B). There was
no change in seronegative or seropositive individuals
IgM or IgA titers against NP over the course of vaccination as expected (Fig. 3A, B). These results indicated
that immunization with SARS-CoV-2 vaccines could
elicit IgM and IgA isotype antibodies in seronegative individuals, but not for individuals with a previous history
of infection.
IgG subclass response to SARS-CoV-2

There are four IgG subclasses (IgG1, IgG2, IgG3, IgG4)
that differ in efficiencies in recruiting immune effector

Fig. 2 Antibody response to primary immunization based on sex and age. A Results of the neutralization proxy blocking assay after primary
immunization at week 3 with individuals stratified by sex (male, female) or age (18–49 years old, ≥ 50 years old). Each point represents an
individual 3 weeks after the first dose of vaccine (week 3). Bars represent the group median. Statistical tests for significant differences between
groups were unpaired, two-tailed Wilcoxon-Mann-Whitney test with a significant threshold of P < 0.05
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Fig. 3 IgM and IgA antibody isotype responses to SARS-CoV-2 after immunization. A, B Multiplex bead-based antibody binding assay that measures the IgM
(A) or IgA-specific (B) antibody response to 4 SARS-CoV-2 viral antigens (S1, S2, RBD, and NP). Median Fluorescent Intensity (MFI) is shown and background well
subtraction has been used to remove the nonspecific signal. Each dot represents an individual at baseline before vaccine (week 0), 3 weeks after the first dose
of BNT162b2 COVID-19 vaccine (week 3) or 4 weeks after the second dose of BNT162b2 COVID-19 vaccine (week 7). Bars represent the group median.
The number of individuals in each group are shown below the graphs in Fig. 1. Individuals with a previous history of SARS-CoV-2 infection (seropositive; blue),
no previous history of infection (seronegative; red), and individuals with possible undiagnosed infection (green). The dashed line indicates a threshold
determined by the sum of the mean and standard deviation for the negative control (beads without antigen). Statistical tests for significant differences between
groups were unpaired, two-tailed Wilcoxon-Mann-Whitney test with a significant threshold of P < 0.05
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cells [26, 27]. In a recent study, it was determined that
SARS-CoV-2-infected individuals make IgG1 and IgG3
subclass antibody responses to the spike RBD with little
contribution from IgG2 or IgG4 subclasses [28]. Using
IgG subclass-specific enzyme-linked immunosorbent assays (ELISAs), we found that in 24 SARS-CoV-2-infected
individuals at baseline before immunization, IgG1 and
IgG3 were the dominant subclasses for spike protein S1,
S2, and RBD subunits and the NP (Fig. 4A; Additional
file 1: Figure S3). Only two individuals made low titer
IgG2 responses, and no individuals had detectable IgG4
antibody responses (Fig. 4A; Additional file 1: Figure S3).
Similarly, after primary immunization with SARS-CoV-2
vaccine, seronegative individuals displayed the same pattern of subclass response to the spike RBD when compared to seropositive individuals at baseline, with IgG1
and IgG3 levels being the highest. These results indicated
that similar class-switch antibody responses to SARSCoV-2 spike protein occurred after both vaccination and
natural infection (Fig. 4B; Additional file 1: Figure S3).
High-resolution antibody epitope determination by SARSCoV-2 spike peptide microarray

Finally, we selected 14 seronegative individuals after primary immunization with the SARS-CoV-2 vaccine (week
3) and determined linear epitopes recognized by
humoral immune responses using a SARS-CoV-2 spike
peptide microarray that contained 196 soluble 12-mer
overlapping peptides (Additional file 2). Heatmaps using
the Log2 MFI values for each peptide were displayed for
each spike subunit (Fig. 5; Additional file 3). Using a
threshold of mean Z-score greater than 1 as “immunodominant,” we found that a peptide in the RBD (S1-61)
was the most immunodominant in the S1 region, targeted by antibodies from most individuals tested (Fig.
5A; Additional file 4). There were also three other

Page 8 of 12

peptides in the RBD that had high antibody binding
levels (S1–66, S1–72, S1–76), with only one occurring in
the region identified to make critical contacts with host
cell receptor ACE2 (S1-76; Fig. 5A). Outside of the RBD,
there were also peptides highly recognized by antibodies
within the N-terminal domain (NTD; S1–24, S1–34, S1–
45) and near the S1/S2 cleavage site (S1–111, S1–105,
S1–97; Fig. 5A). In the S2, the antibody response was
mainly targeted to four peptides in the C-terminal region near the heptad repeat 2 (HR2), transmembrane,
and cytoplasmic domains (S2–78, 21–81, S2–83, S2–94),
but there was a single peptide in the heptad repeat 1
(HR1) domain that was also immunodominant (S2–47;
Fig. 5B, Additional file 4). This data identified regions in
the spike protein that are commonly recognized by antibodies from many SARS-CoV-2 vaccinated individuals
and may reveal epitopes critical for vaccine-mediated
protection.

Discussion
We observed equivalent antibody levels after a single
dose of BNT162b2 SARS-CoV-2 vaccine in previously
infected SARS-CoV-2 seropositive individuals compared
to seronegative individuals after two doses of vaccine.
This observation is in line with several previous studies
that showed after a single dose of SARS-CoV-2 mRNA
vaccine, seropositive individuals had significantly higher
titers when compared with seronegative individuals with
no history of previous infection [16–19]. The data presented here imply that a second dose of vaccine in seropositive individuals does not significantly boost the
antibody titers higher. This observation was also reported in another recent study [29]. One limitation of
our study is that there may be smaller magnitude increases in antibody titers in the seropositive group after
the second dose that is limited by our immunoassay

Fig. 4 IgG subclass responses to SARS-CoV-2. A, B Dot plots of ELISA End Point titers calculated as the highest plasma dilution where the O.D. is
3× background. The bar represents the group median, and the points display individual data. Secondary antibodies specific for each IgG subclass
(IgG1, IgG2, IgG3, IgG4) were used to determine subclass-specific responses. A Subclass responses to SARS-CoV-2 spike subunits (S1, S2) and
nucleocapsid protein (NP) in SARS-CoV-2 infected individuals (n = 24) at baseline before the vaccine. B Subclass responses to SARS-CoV-2
receptor-binding domain (RBD) in SARS-CoV-2 infected individuals at baseline before vaccine (seropositive; n = 24) and three weeks after the first
dose of BNT162b2 COVID-19 vaccine in seronegative individuals (vaccine; n = 24)
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Fig. 5 High-resolution mapping of SARS-CoV-2 antibody responses after COVID-19 vaccine. A, B Plasma IgG binding to SARS-CoV-2 peptides
spanning the SARS-CoV-2 spike protein (A S1 and B S2 subunits separated;12-mer overlapping peptides) in 14 SARS-CoV-2 seronegative adults
after primary COVID-19 immunization (week 3). Each peptide was printed in triplicate and the log2 of the average median fluorescent intensity
(F635) for each peptide graphed. Row color corresponds to the minimum and maximum intensity for all peptides for each individual. Known
regions of the spike protein are annotated above heatmaps. Orange section in RBD depicts critical ACE2 contact residues. Line graphs displaying
the mean group Z-score for each peptide in S1 and S2 from the vaccine group (blue; n = 14)

detection platform. Improved assays with standard concentrations and dilution series along with further study
of antibody functionality will be required to determine
what are the benefits of repeated doses in both seropositive and seronegative individuals. Despite these observations, the impact of prior infection on other parameters
of immunity, such as T cell-mediated immunity, as well
as the duration of vaccine-mediated protection need further evaluation. Moreover, we only compared individuals
that had prior infection 30–60 days before primary
immunization to individuals with no history of infection,
indicating that future studies are needed to determine if

there are differences in antibody responses to vaccination in individuals who had prior infection beyond 60
days. Another limitation of our study is that there was
an overrepresentation of women and individuals that
identify as White compared to other ethnicities due to
the demographics of our health care workers. Future
studies will be required to efficiently determine the role
of sex and ethnicity in the antibody response to SARSCoV-2 vaccines. The lack of robust immune correlates
of protection for the SARS-CoV-2 vaccines in humans
impedes serial monitoring of protective immunity in
these populations. Further definition of immune
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correlates of protection for these vaccines will allow potential alterations in vaccine regimens for specific
individuals.
While IgG isotype antibodies are typically targeted for
vaccines and therapeutics, IgA and IgM isotypes can play
critical roles in protecting mucosal surfaces from pathogens. IgA antibodies have been shown to neutralize
SARS-CoV-2 [30] and elevated levels of IgA in the blood
are associated with influenza vaccine efficacy [31, 32].
We found that peripheral blood SARS-CoV-2 spike protein IgM and IgA responses were boosted after primary
exposure in seronegative individuals but were not significantly increased in seropositive individuals during vaccination, or after the second dose of vaccine in
seronegative individuals. This may indicate a peak response generated by primary exposure that is difficult to
further boost in the blood by repeated exposure to antigen. Moreover, we further defined the contributions of
the four IgG subclasses to SARS-CoV-2 binding and
found that similar to natural infection, IgG1 and IgG3
dominated the response, with little contribution by IgG2
and IgG4 subclasses. Vaccine-elicited antibodies of different subclasses can differentially recruit and activate
innate immune effector cells which express antibody receptors on their surface and this can significantly impact
vaccine efficacy [33, 34]. During SARS-CoV-2 infection
it has been shown that neutralizing antibodies rapidly
develop and are predominantly IgG1 or IgG3 subclass
[28]. These data demonstrated that vaccination could
elicit similar antibody class-switching as observed during
natural infection but the contributions to long-term immunity need further study.
Finally, we used a SARS-CoV-2 peptide array to identify immunodominant linear epitopes targeted by antibodies after vaccination. Studies from convalescent
individuals with SARS-CoV-2 infection identified dominant neutralizing epitopes within the RBD as well as
outside the RBD in the S1 and S2 regions of the spike
protein [35, 36]. The two most immunodominant peptides were S1-61 within the receptor-binding domain
and S2–78 at the C-terminal of the spike protein adjacent to the HR2. The peptide sequence of S1–61 is outside of the amino acid motif that contacts ACE2 so the
significance of this epitope or its functional role is unclear and not described in previous studies. However,
the peptide S2–78 has also been observed to be a region
of immunodominance in antibody serology studies of
natural SARS-CoV-2 infection [36–38]. Moreover, antibody response levels to this peptide have been shown to
have a neutralizing activity and were associated with decreased COVID-19 disease severity [36, 37]. These observations raise the possibility that epitopes outside of
the RBD that do not directly block the RBD-ACE2 interaction could be utilized to mitigate viral entry through
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other critical mechanisms. Similarly, we found that after
primary immunization there are linear epitopes outside
the RBD that are targeted by antibodies observed in
many individuals. Future studies to determine if antibodies targeting these epitopes can neutralize the virus
will unveil possible new viral mechanisms of action and
targets for novel vaccine formulations.

Conclusions
In conclusion, this study provides a high-resolution definition of the antibody responses to SARS-CoV-2 mRNA
vaccination in individuals that had SARS-CoV-2 infection compared with individuals with no prior history of
infection. Future studies of other immune parameters
and the durability of immunity will be required to alter
immunization regimens based on prior viral or vaccine
exposure.
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